2,5-二甲基-3-呋喃基甲胺 | 306934-85-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 2,5-二甲基-3-呋喃基甲胺
• 中文别名: (2,5-二甲基-3-呋喃基)甲胺
• 英文名称: (2,5-dimethylfuran-3-yl)methanamine
• 英文别名: (2,5-dimethyl-3-furyl)methylamine
• CAS: 306934-85-0
• 化学式: C₇H₁₁NO
• 分子量: 125.17
• InChiKey: AGQXLVABIKZJJG-UHFFFAOYSA-N

物化性质

• 沸点：
  42-56°C/0.1mm
• 密度：
  1.003±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  39.2
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 安全说明：
  S26,S36/37/39
• 危险类别码：
  R36/37/38
• 海关编码：
  2932190090

SDS

Name:	(2 5-Dimethyl-3-furyl)methylamine 97% Material Safety Data Sheet
Synonym:
CAS:	306934-85-0

Section 1 - Chemical Product MSDS Name:(2 5-Dimethyl-3-furyl)methylamine 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
306934-85-0	(2,5-Dimethyl-3-furyl)methylamine	97%	unlisted

Hazard Symbols: C
Risk Phrases: 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 306934-85-0: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid or liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: 42 - 56 deg C @0.1mmHg
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C7H11NO
Molecular Weight: 125

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, acids, acid chlorides, halogens, halogenated agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide, acrid smoke and fumes.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 306934-85-0 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
(2,5-Dimethyl-3-furyl)methylamine - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.*
Hazard Class: 8
UN Number: 2735
Packing Group: III
IMO
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing Group: III
RID/ADR
Shipping Name: AMINES, LIQUID, CORROSIVE, N.O.S.
Hazard Class: 8
UN Number: 2735
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 306934-85-0: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 306934-85-0 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 306934-85-0 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,5-二甲基-3-呋喃基甲胺 、 4-氰基苯磺酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 5.0h， 生成 4-cyano-N-((2,5-dimethylfuran-3-yl)methyl)-benzenesulfonamide
  参考文献：
  名称：

  设计和合成基于杂芳基的苯磺酰胺衍生物作为H5N1甲型流感病毒的有效抑制剂†

  摘要：

  甲型流感病毒是一种包膜的负性单链RNA病毒，可引起发热的呼吸道感染，对人类健康乃至全世界的生命都构成了具有临床挑战性的威胁。更令人震惊的是高致病性禽流感（HPAI）菌株（如H5N1）的出现，其在人类感染中的死亡率（60％）比季节性流感菌株高得多。在这项研究中，新的杂芳基苯磺酰胺衍生物系列被确定为M2质子通道抑制剂。对结构-活性关系的系统研究和分子对接研究表明，磺酰胺部分和2,5-二甲基取代的噻吩作为核心结构在抗流感活性中起着重要作用。在衍生物中，化合物11k具有对H5N1病毒的优异抗病毒活性，EC 50值为0.47μM，选择性指数为119.9，与参考药物金刚烷胺相当。

  DOI：

  10.1039/c8md00474a
• 作为产物：
  描述：

  2,5-二甲基-3-呋喃酸 在 ammonium hydroxide 、 lithium aluminium tetrahydride 、 氯化亚砜 作用下， 以 四氢呋喃 、 二氯甲烷 、 水 、 甲苯 为溶剂， 反应 7.0h， 生成 2,5-二甲基-3-呋喃基甲胺
  参考文献：
  名称：

  设计和合成基于杂芳基的苯磺酰胺衍生物作为H5N1甲型流感病毒的有效抑制剂†

  摘要：

  甲型流感病毒是一种包膜的负性单链RNA病毒，可引起发热的呼吸道感染，对人类健康乃至全世界的生命都构成了具有临床挑战性的威胁。更令人震惊的是高致病性禽流感（HPAI）菌株（如H5N1）的出现，其在人类感染中的死亡率（60％）比季节性流感菌株高得多。在这项研究中，新的杂芳基苯磺酰胺衍生物系列被确定为M2质子通道抑制剂。对结构-活性关系的系统研究和分子对接研究表明，磺酰胺部分和2,5-二甲基取代的噻吩作为核心结构在抗流感活性中起着重要作用。在衍生物中，化合物11k具有对H5N1病毒的优异抗病毒活性，EC 50值为0.47μM，选择性指数为119.9，与参考药物金刚烷胺相当。

  DOI：

  10.1039/c8md00474a

文献信息

• Novel flavors, flavor modifiers, tastants, taste enhancers, umami or sweet tastants, and/or enhancers and use thereof
  申请人：Tachdjian Catherine

  公开号：US20050084506A1

  公开（公告）日：2005-04-21

  The present invention relates to the discovery that certain non-naturally occurring, non-peptide amide compounds and amide derivatives, such as oxalamides, ureas, and acrylamides, are useful flavor or taste modifiers, such as a flavoring or flavoring agents and flavor or taste enhancer, more particularly, savory (the “umami” taste of monosodium glutamate) or sweet taste modifiers,—savory or sweet flavoring agents and savory or sweet flavor enhancers, for food, beverages, and other comestible or orally administered medicinal products or compositions.

  本发明涉及发现，某些非天然存在的非肽酰胺化合物和酰胺衍生物，如草酰胺、脲和丙烯酰胺，可用作风味或口味调节剂，例如风味或调味剂和风味或口味增强剂，更具体地说，是用于食品、饮料和其他可食用或口服药品或组合物的风味或口味调节剂，包括鲜味（味精的“鲜味”）或甜味调节剂，鲜味或甜味调味剂以及鲜味或甜味增强剂。
• 2,4-Pyrimidinediamine Compounds and Their Uses
  申请人：Singh Rajinder

  公开号：US20150266828A1

  公开（公告）日：2015-09-24

  The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and prevention of diseases characterized by, caused by or associated with the release of chemical mediators via degranulation and other processes effected by activation of the IgE and/or IgG receptor signaling cascades.

  本发明提供了抑制IgE和/或IgG受体信号级联反应的2,4-嘧啶二胺化合物，该级联反应导致化学介质的释放，以及合成这些化合物的中介体和方法，以及在多种情况下使用这些化合物的方法，包括在治疗和预防由脱粒和其他由IgE和/或IgG受体信号级联反应激活引起的化学介质释放所表征、引起或相关的疾病。
• Hepatitis C virus polymerase inhibitors
  申请人：Blaney Jeffrey Mark

  公开号：US20080200512A1

  公开（公告）日：2008-08-21

  The invention provides a compound of formula: and methods for making and using the same, where R 1 and R 2 are independently hydrogen, C 1-6 alkyl or C 1-6 haloalkyl; R 3 is hydrogen, halogen, C 1-6 alkyl or C 1-6 alkoxy; R 4 is hydrogen or halogen; and R 5 is a mono- or di-amino acid moiety, a succinic acid moiety, a urea moiety, or a derivative thereof. The invention also provides pharmaceutical compositions comprising a compound of formula I, and methods for making and using the same.

  这项发明提供了一个化合物的公式：以及制备和使用该化合物的方法，其中R1和R2分别是氢、C1-6烷基或C1-6卤代烷基；R3是氢、卤素、C1-6烷基或C1-6烷氧基；R4是氢或卤素；R5是单氨基酸或双氨基酸基团、琥珀酸基团、尿素基团或其衍生物。该发明还提供了包含化合物I的药物组合物，以及制备和使用该药物组合物的方法。
• [EN] TRICYCLIC AKR1C3 DEPENDENT KARS INHIBITORS<br/>[FR] INHIBITEURS DE KARS DÉPENDANT D'AKR1C3 TRICYCLIQUES
  申请人：NOVARTIS AG

  公开号：WO2021005586A1

  公开（公告）日：2021-01-14

  The present invention relates to novel tricyclic compounds that are AKR1C3 dependent KARS inhibitor, processes for their preparation, pharmaceutical compositions, and medicaments containing them, and their use in diseases and disorders mediated by an AKR1C3 dependent KARS inhibitor.

  本发明涉及新型三环化合物，这些化合物是AKR1C3依赖的KARS抑制剂，涉及其制备方法、药物组合物、含有它们的药物以及它们在由AKR1C3依赖的KARS抑制剂介导的疾病和疾患中的应用。
• Benzimidazoles
  申请人：Edwards L. Michael

  公开号：US20060014756A1

  公开（公告）日：2006-01-19

  The invention is directed to physiologically active compounds of the general formula (Ix) and compositions containing such compounds, and their prodrugs, and pharmaceutically acceptable salts and solvates of such compounds and their prodrugs, as well as to novel compounds within the scope of formula (Ix), and to processes for their preparation. Such compounds and compositions have valuable pharmaceutical properties, in particular the ability to inhibit kinases.

  本发明涉及一般式（Ix）的生理活性化合物及含有这种化合物的组合物，以及它们的前药、药学上可接受的盐和溶剂化物，还涉及在式（Ix）范围内的新化合物和它们的制备方法。这种化合物和组合物具有有价值的药物性质，特别是抑制激酶的能力。